{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:40:18Z","timestamp":1740469218238,"version":"3.37.3"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40291-024-00761-7","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T10:29:00Z","timestamp":1737109740000},"page":"183-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A miRNA-Based Approach in Autosomal Dominant Polycystic Kidney Disease: Challenges and Insights from Adult to Pediatric Evidence"],"prefix":"10.1007","volume":"29","author":[{"given":"Caterina","family":"Vitulano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmario","family":"Forcina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Colosimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Frattolillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa Valentina","family":"Villani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Marzuillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Miraglia del Giudice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5877-3757","authenticated-orcid":false,"given":"Anna","family":"Di Sessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"issue":"1","key":"761_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/genes15010091","volume":"15","author":"M Satariano","year":"2024","unstructured":"Satariano M, Ghose S, Raina R. The pathophysiology of inherited renal cystic diseases. Genes (Basel). 2024;15(1):91.","journal-title":"Genes (Basel)."},{"issue":"2","key":"761_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/MOP.0000000000000195","volume":"27","author":"MA Cadnapaphornchai","year":"2015","unstructured":"Cadnapaphornchai MA. Autosomal dominant polycystic kidney disease in children. Curr Opin Pediatr. 2015;27(2):193\u2013200.","journal-title":"Curr Opin Pediatr"},{"issue":"10174","key":"761_CR3","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","volume":"393","author":"E Cornec-Le Gall","year":"2019","unstructured":"Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019;393(10174):919\u201335.","journal-title":"Lancet"},{"issue":"1","key":"761_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4(1):50.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"761_CR5","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1681\/ASN.2015050583","volume":"27","author":"CM Heyer","year":"2016","unstructured":"Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, et al. Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(9):2872\u201384.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"761_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"E Cornec-Le Gall","year":"2016","unstructured":"Cornec-Le Gall E, Audr\u00e9zet MP, Rousseau A, Hourmant M, Renaudineau E, Charasse C, et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(3):942\u201351.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"761_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000529119","volume":"49","author":"M Pietrzak-Nowacka","year":"2024","unstructured":"Pietrzak-Nowacka M, Safranow K, P\u0142o\u0144ska-Go\u015bciniak E, Nowacki A, P\u00f3\u017aniak P, Gutowski P, et al. Cardiovascular involvement in patients with autosomal dominant polycystic kidney disease: a review. Kidney Blood Press Res. 2024;49(1):9\u201319.","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"761_CR8","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.3390\/ijms25052554","volume":"25","author":"M Righini","year":"2024","unstructured":"Righini M, Mancini R, Busutti M, Buscaroli A. Autosomal dominant polycystic kidney disease: extrarenal involvement. Int J Mol Sci. 2024;25(5):2554.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"761_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cgh.2014.07.051","volume":"13","author":"MC Hogan","year":"2015","unstructured":"Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, et al. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2015;13(1):155-64.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"761_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.cell.2009.08.045","volume":"139","author":"R Sharif-Naeini","year":"2009","unstructured":"Sharif-Naeini R, Folgering JH, Bichet D, Duprat F, Lauritzen I, Arhatte M, et al. Polycystin-1 and -2 dosage regulates pressure sensing. Cell. 2009;139(3):587\u201396.","journal-title":"Cell"},{"issue":"5","key":"761_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2019.100887","volume":"66","author":"GB Colbert","year":"2020","unstructured":"Colbert GB, Elrggal ME, Gaur L, Lerma EV. Update and review of adult polycystic kidney disease. Dis Mon. 2020;66(5): 100887.","journal-title":"Dis Mon"},{"issue":"4","key":"761_CR12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1053\/j.ajkd.2014.05.020","volume":"64","author":"S Reule","year":"2014","unstructured":"Reule S, Sexton DJ, Solid CA, Chen SC, Collins AJ, Foley RN. ESRD from autosomal dominant polycystic kidney disease in the United States, 2001\u20132010. Am J Kidney Dis. 2014;64(4):592.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"761_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12882-024-03484-3","volume":"25","author":"D Mladsi","year":"2024","unstructured":"Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, et al. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024;25(1):56.","journal-title":"BMC Nephrol"},{"key":"761_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-981-10-2041-4_2","volume":"933","author":"DY Kim","year":"2016","unstructured":"Kim DY, Park JH. Genetic mechanisms of ADPKD. Adv Exp Med Biol. 2016;933:13\u201322.","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"761_CR15","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/humu.22708","volume":"35","author":"E Cornec-Le Gall","year":"2014","unstructured":"Cornec-Le Gall E, Audr\u00e9zet MP, Le Meur Y, Chen JM, F\u00e9rec C. Genetics and pathogenesis of autosomal dominant polycystic kidney disease: 20 years on. Hum Mutat. 2014;35(12):1393\u2013406.","journal-title":"Hum Mutat"},{"issue":"671","key":"761_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.gene.2018.05.112","volume":"10","author":"M Abdelwahed","year":"2018","unstructured":"Abdelwahed M, Hilbert P, Ahmed A, Mahfoudh H, Bouomrani S, Dey M, et al. Mutational analysis in patients with autosomal dominant polycystic kidney disease (ADPKD): identification of five mutations in the PKD1 gene. Gene. 2018;10(671):28\u201335.","journal-title":"Gene"},{"issue":"1","key":"761_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1681\/ASN.2017050483","volume":"29","author":"E Cornec-Le Gall","year":"2018","unstructured":"Cornec-Le Gall E, Torres VE, Harris PC. Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol. 2018;29(1):13\u201323.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"761_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nrneph.2009.13","volume":"5","author":"T Ecder","year":"2009","unstructured":"Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol. 2009;5(4):221\u20138.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"761_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1053\/j.akdh.2023.03.004","volume":"30","author":"FF Rahbari-Oskoui","year":"2023","unstructured":"Rahbari-Oskoui FF. Management of hypertension and associated cardiovascular disease in autosomal dominant polycystic kidney disease. Adv Kidney Dis Health. 2023;30(5):417\u201328.","journal-title":"Adv Kidney Dis Health."},{"issue":"4","key":"761_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2023.151434","volume":"43","author":"C Hanna","year":"2023","unstructured":"Hanna C, Iliuta IA, Besse W, Mekahli D, Chebib FT. Cystic kidney diseases in children and adults: differences and gaps in clinical management. Semin Nephrol. 2023;43(4): 151434.","journal-title":"Semin Nephrol"},{"issue":"3","key":"761_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1053\/j.akdh.2023.01.007","volume":"30","author":"A Dachy","year":"2023","unstructured":"Dachy A, Van Loo L, Mekahli D. Autosomal dominant polycystic kidney disease in children and adolescents: assessing and managing risk of progression. Adv Kidney Dis Health. 2023;30(3):236\u201344.","journal-title":"Adv Kidney Dis Health."},{"issue":"11","key":"761_CR22","doi-asserted-by":"publisher","first-page":"1274435","DOI":"10.3389\/fped.2023.1274435","volume":"10","author":"I Sori\u0107 Hosman","year":"2023","unstructured":"Sori\u0107 Hosman I, Cvitkovi\u0107 Roi\u0107 A, Fi\u0161trek Prli\u0107 M, Vukovi\u0107 Brinar I, Lamot L. Predicting autosomal dominant polycystic kidney disease progression: review of promising serum and urine biomarkers. Front Pediatr. 2023;10(11):1274435.","journal-title":"Front Pediatr"},{"issue":"2","key":"761_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40620-021-01062-6","volume":"35","author":"I Capuano","year":"2022","unstructured":"Capuano I, Buonanno P, Riccio E, Amicone M, Pisani A. Therapeutic advances in ADPKD: the future awaits. J Nephrol. 2022;35(2):397\u2013415.","journal-title":"J Nephrol"},{"key":"761_CR24","doi-asserted-by":"publisher","unstructured":"Riccio E, Amicone M, Capuano I, Pacella D, Pisani A. Octreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience. J Nephrol. 2024 Nov 6. https:\/\/doi.org\/10.1007\/s40620-024-02145-w.","DOI":"10.1007\/s40620-024-02145-w"},{"issue":"8","key":"761_CR25","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.mayocp.2015.05.011","volume":"90","author":"MC Hogan","year":"2015","unstructured":"Hogan MC, Masyuk T, Bergstralh E, Li B, Kremers WK, Vaughan LE, et al. Efficacy of 4 years of octreotide long-acting release therapy in patients with severe polycystic liver disease. Mayo Clin Proc. 2015;90(8):1030\u20137.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"761_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5414\/CN110510","volume":"97","author":"I Capuano","year":"2022","unstructured":"Capuano I, Buonanno P, Riccio E, Rizzo M, Pisani A. Tolvaptan vs. somatostatin in the treatment of ADPKD: a review of the literature. Clin Nephrol. 2022;97(3):131\u201340.","journal-title":"Clin Nephrol"},{"key":"761_CR27","first-page":"2020-vol3","volume":"37","author":"M Amicone","year":"2020","unstructured":"Amicone M, Riccio E, Angelucci V, Pisani A. Tolvaptan in ADPKD: a turning point or an unsustainable therapy? One year of \u201creal life\u201d experience. G Ital Nefrol. 2020;37:2020-vol3.","journal-title":"G Ital Nefrol"},{"key":"761_CR28","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1001\/jama.2018.15870","volume":"320","author":"E Meijer","year":"2018","unstructured":"Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D\u2019Agnolo HMA, DIPAK-1 Investigators, et al. Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial. JAMA. 2018;320:2010\u20139.","journal-title":"JAMA"},{"key":"761_CR29","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cgh.2015.12.049","volume":"14","author":"A Pisani","year":"2016","unstructured":"Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, ALADIN Study Group, et al. Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease. Clin Gastroenterol Hepatol. 2016;14:1022-30.e4.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"761_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2215\/CJN.0000000000000049","volume":"18","author":"M Trillini","year":"2023","unstructured":"Trillini M, Caroli A, Perico N, Remuzzi A, Brambilla P, Villa G, TOOL Study Group, et al. Effects of octreotide-long-acting release added-on tolvaptan in patients with autosomal dominant polycystic kidney disease: pilot, randomized, placebo-controlled, cross-over trial. Clin J Am Soc Nephrol. 2023;18(2):223\u201333.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"761_CR31","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1172\/JCI64401","volume":"123","author":"X Zhou","year":"2013","unstructured":"Zhou X, Fan LX, Sweeney WE Jr, Denu JM, Avner ED, Li X. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J Clin Invest. 2013;123(7):3084\u201398.","journal-title":"J Clin Invest"},{"issue":"3","key":"761_CR32","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/cphy.c160018","volume":"7","author":"J Ghata","year":"2017","unstructured":"Ghata J, Cowley BD Jr. Polycystic kidney disease. Compr Physiol. 2017;7(3):945\u201375.","journal-title":"Compr Physiol"},{"issue":"4","key":"761_CR33","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/MNH.0000000000000333","volume":"26","author":"M Yheskel","year":"2017","unstructured":"Yheskel M, Patel V. Therapeutic microRNAs in polycystic kidney disease. Curr Opin Nephrol Hypertens. 2017;26(4):282\u20139.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"761_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3674","volume":"26","author":"H Ali","year":"2024","unstructured":"Ali H, Malik MZ, Abu-Farha M, Abubaker J, Cherian P, Nizam R, et al. Global analysis of urinary extracellular vesicle small RNAs in autosomal dominant polycystic kidney disease. J Gene Med. 2024;26(2): e3674.","journal-title":"J Gene Med"},{"issue":"13","key":"761_CR35","doi-asserted-by":"publisher","first-page":"1006427","DOI":"10.3389\/fphys.2022.1006427","volume":"20","author":"Q Zheng","year":"2022","unstructured":"Zheng Q, Reid G, Eccles MR, Stayner C. Non-coding RNAs as potential biomarkers and therapeutic targets in polycystic kidney disease. Front Physiol. 2022;20(13):1006427.","journal-title":"Front Physiol"},{"issue":"5","key":"761_CR36","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3390\/medicina59050915","volume":"59","author":"C Pana","year":"2023","unstructured":"Pana C, Stanigut AM, Cimpineanu B, Alexandru A, Salim C, Nicoara AD, et al. Urinary biomarkers in monitoring the progression and treatment of autosomal dominant polycystic kidney disease: the promised land? Medicina (Kaunas). 2023;59(5):915.","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"761_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/MOP.0000000000000168","volume":"27","author":"YL Phua","year":"2015","unstructured":"Phua YL, Ho J. MicroRNAs in the pathogenesis of cystic kidney disease. Curr Opin Pediatr. 2015;27(2):219\u201326.","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"761_CR38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/genes13020191","volume":"13","author":"LM Ruiz-Manriquez","year":"2022","unstructured":"Ruiz-Manriquez LM, Ledesma Pacheco SJ, Medina-Gomez D, Uriostegui-Pena AG, Estrada-Meza C, Bandyopadhyay A, et al. A brief review on the regulatory roles of microRNAs in cystic diseases and their use as potential biomarkers. Genes (Basel). 2022;13(2):191.","journal-title":"Genes (Basel)."},{"key":"761_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109548","volume":"71","author":"H Ramalingam","year":"2020","unstructured":"Ramalingam H, Yheskel M, Patel V. Modulation of polycystic kidney disease by non-coding RNAs. Cell Signal. 2020;71: 109548.","journal-title":"Cell Signal"},{"issue":"26","key":"761_CR40","doi-asserted-by":"publisher","first-page":"10765","DOI":"10.1073\/pnas.1301693110","volume":"110","author":"V Patel","year":"2013","unstructured":"Patel V, Williams D, Hajarnis S, Hunter R, Pontoglio M, Somlo S, et al. miR-17~92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. Proc Natl Acad Sci USA. 2013;110(26):10765\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"761_CR41","doi-asserted-by":"publisher","first-page":"14395","DOI":"10.1038\/ncomms14395","volume":"16","author":"S Hajarnis","year":"2017","unstructured":"Hajarnis S, Lakhia R, Yheskel M, Williams D, Sorourian M, Liu X, et al. microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism. Nat Commun. 2017;16(8):14395.","journal-title":"Nat Commun"},{"issue":"7043","key":"761_CR42","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nature03552","volume":"435","author":"L He","year":"2005","unstructured":"He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828\u201333.","journal-title":"Nature"},{"issue":"9","key":"761_CR43","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1158\/0008-5472.CAN-03-3773","volume":"64","author":"A Ota","year":"2004","unstructured":"Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004;64(9):3087\u201395.","journal-title":"Cancer Res"},{"issue":"2","key":"761_CR44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2008.04.001","volume":"133","author":"JT Mendell","year":"2008","unstructured":"Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008;133(2):217\u201322.","journal-title":"Cell"},{"issue":"3","key":"761_CR45","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/PPO.0b013e318258b60a","volume":"18","author":"CP Concepcion","year":"2012","unstructured":"Concepcion CP, Bonetti C, Ventura A. The microRNA-17-92 family of microRNA clusters in development and disease. Cancer J. 2012;18(3):262\u20137.","journal-title":"Cancer J"},{"issue":"2","key":"761_CR46","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jmb.2004.03.065","volume":"339","author":"A Tanzer","year":"2004","unstructured":"Tanzer A, Stadler PF. Molecular evolution of a microRNA cluster. J Mol Biol. 2004;339(2):327\u201335.","journal-title":"J Mol Biol"},{"issue":"7","key":"761_CR47","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1681\/ASN.2013040390","volume":"25","author":"AK Marrone","year":"2014","unstructured":"Marrone AK, Stolz DB, Bastacky SI, Kostka D, Bodnar AJ, Ho J. MicroRNA-17~92 is required for nephrogenesis and renal function. J Am Soc Nephrol. 2014;25(7):1440\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"761_CR48","doi-asserted-by":"publisher","first-page":"F993","DOI":"10.1152\/ajprenal.00450.2018","volume":"316","author":"YL Phua","year":"2019","unstructured":"Phua YL, Chen KH, Hemker SL, Marrone AK, Bodnar AJ, Liu X, et al. Loss of miR-17~92 results in dysregulation of Cftr in nephron progenitors. Am J Physiol Renal Physiol. 2019;316(5):F993-1005.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"10","key":"761_CR49","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/ng.915","volume":"43","author":"L de Pontual","year":"2011","unstructured":"de Pontual L, Yao E, Callier P, Faivre L, Drouin V, Cariou S, et al. Germline deletion of the miR-17\u223c92 cluster causes skeletal and growth defects in humans. Nat Genet. 2011;43(10):1026\u201330.","journal-title":"Nat Genet"},{"issue":"12","key":"761_CR50","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/cdd.2013.125","volume":"20","author":"E Mogilyansky","year":"2013","unstructured":"Mogilyansky E, Rigoutsos I. The miR-17\/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013;20(12):1603\u201314.","journal-title":"Cell Death Differ"},{"issue":"2","key":"761_CR51","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ydbio.2007.08.007","volume":"310","author":"Y Lu","year":"2007","unstructured":"Lu Y, Thomson JM, Wong HY, Hammond SM, Hogan BL. Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol. 2007;310(2):442\u201353.","journal-title":"Dev Biol"},{"issue":"6","key":"761_CR52","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1007\/s11033-009-9861-3","volume":"37","author":"H Sun","year":"2010","unstructured":"Sun H, Li QW, Lv XY, Ai JZ, Yang QT, Duan JJ, et al. MicroRNA-17 post-transcriptionally regulates polycystic kidney disease-2 gene and promotes cell proliferation. Mol Biol Rep. 2010;37(6):2951\u20138.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"761_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cell.2004.12.035","volume":"120","author":"BP Lewis","year":"2005","unstructured":"Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15\u201320.","journal-title":"Cell"},{"issue":"11","key":"761_CR54","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1172\/JCI64313","volume":"122","author":"K Hopp","year":"2012","unstructured":"Hopp K, Ward CJ, Hommerding CJ, Nasr SH, Tuan HF, Gainullin VG, et al. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest. 2012;122(11):4257\u201373.","journal-title":"J Clin Invest"},{"issue":"8","key":"761_CR55","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/ki.2008.686","volume":"75","author":"S Rossetti","year":"2009","unstructured":"Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int. 2009;75(8):848\u201355.","journal-title":"Kidney Int"},{"issue":"11","key":"761_CR56","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1681\/ASN.2010101080","volume":"22","author":"C Bergmann","year":"2011","unstructured":"Bergmann C, von Bothmer J, Ortiz Br\u00fcchle N, Venghaus A, Frank V, Fehrenbach H, et al. Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. J Am Soc Nephrol. 2011;22(11):2047\u201356.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"761_CR57","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/sj.emboj.7600160","volume":"23","author":"L Gresh","year":"2004","unstructured":"Gresh L, Fischer E, Reimann A, Tanguy M, Garbay S, Shao X, et al. A transcriptional network in polycystic kidney disease. EMBO J. 2004;23(7):1657\u201368.","journal-title":"EMBO J"},{"issue":"5","key":"761_CR58","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","volume":"134","author":"PP Hsu","year":"2008","unstructured":"Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134(5):703\u20137.","journal-title":"Cell"},{"issue":"6","key":"761_CR59","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2350\/08-10-0548.1","volume":"12","author":"K Meir","year":"2009","unstructured":"Meir K, Fellig Y, Meiner V, Korman SH, Shaag A, Nadjari M, et al. Severe infantile carnitine palmitoyltransferase II deficiency in 19-week fetal sibs. Pediatr Dev Pathol. 2009;12(6):481\u20136.","journal-title":"Pediatr Dev Pathol"},{"issue":"12","key":"761_CR60","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/j.1699-0463.1998.tb00276.x","volume":"106","author":"S Kjaergaard","year":"1998","unstructured":"Kjaergaard S, Graem N, Larsen T, Skovby F. Recurrent fetal polycystic kidneys associated with glutaric aciduria type II. APMIS. 1998;106(12):1188\u201393.","journal-title":"APMIS"},{"issue":"6","key":"761_CR61","doi-asserted-by":"publisher","first-page":"F492","DOI":"10.1152\/ajprenal.00238.2015","volume":"309","author":"VJ Hwang","year":"2015","unstructured":"Hwang VJ, Kim J, Rand A, Yang C, Sturdivant S, Hammock B, et al. The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. Am J Physiol Renal Physiol. 2015;309(6):F492\u20138.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"761_CR62","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.3092","volume":"19","author":"I Rowe","year":"2013","unstructured":"Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med. 2013;19(4):488\u201393.","journal-title":"Nat Med"},{"issue":"8","key":"761_CR63","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a014217","volume":"3","author":"CV Dang","year":"2013","unstructured":"Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med. 2013;3(8): a014217.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"761_CR64","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1074\/jbc.M608939200","volume":"282","author":"Y Sylvestre","year":"2007","unstructured":"Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, et al. An E2F\/miR-20a autoregulatory feedback loop. J Biol Chem. 2007;282(4):2135\u201343.","journal-title":"J Biol Chem"},{"issue":"4","key":"761_CR65","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1074\/jbc.C600252200","volume":"282","author":"K Woods","year":"2007","unstructured":"Woods K, Thomson JM, Hammond SM. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem. 2007;282(4):2130\u20134.","journal-title":"J Biol Chem"},{"issue":"3","key":"761_CR66","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccr.2008.02.013","volume":"13","author":"F Petrocca","year":"2008","unstructured":"Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13(3):272\u201386.","journal-title":"Cancer Cell"},{"key":"761_CR67","doi-asserted-by":"crossref","unstructured":"Mestdagh P, Bostr\u00f6m AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, von Stedingk K, Ghesqui\u00e8re B, Schulte S, Dews M, Thomas-Tikhonenko A, Schulte JH, Zollo M, Schramm A, Gevaert K, Axelson H, Speleman F, Vandesompele J. The miR-17-92 microRNA cluster regulates multiple components of the TGF-\u03b2 pathway in neuroblastoma. Mol Cell. 2010 Dec 10;40(5):762\u201373.","DOI":"10.1016\/j.molcel.2010.11.038"},{"issue":"20","key":"761_CR68","doi-asserted-by":"publisher","first-page":"8233","DOI":"10.1158\/0008-5472.CAN-10-2412","volume":"70","author":"M Dews","year":"2010","unstructured":"Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, et al. The myc-miR-17~92 axis blunts TGF\u03b2 signaling and production of multiple TGF\u03b2-dependent antiangiogenic factors. Cancer Res. 2010;70(20):8233\u201346.","journal-title":"Cancer Res"},{"issue":"11","key":"761_CR69","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nrc1208","volume":"3","author":"PM Siegel","year":"2003","unstructured":"Siegel PM, Massagu\u00e9 J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003;3(11):807\u201321.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"761_CR70","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/s41598-019-38566-y","volume":"9","author":"M Yheskel","year":"2019","unstructured":"Yheskel M, Lakhia R, Cobo-Stark P, Flaten A, Patel V. Anti-microRNA screen uncovers miR-17 family within miR-17~92 cluster as the primary driver of kidney cyst growth. Sci Rep. 2019;9(1):1920.","journal-title":"Sci Rep"},{"issue":"1","key":"761_CR71","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","volume":"10","author":"EC Lee","year":"2019","unstructured":"Lee EC, Valencia T, Allerson C, Schairer A, Flaten A, Yheskel M, et al. Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019;10(1):4148.","journal-title":"Nat Commun"},{"issue":"17","key":"761_CR72","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1002\/pmic.201000501","volume":"11","author":"H Kanzaki","year":"2011","unstructured":"Kanzaki H, Ito S, Hanafusa H, Jitsumori Y, Tamaru S, Shimizu K, et al. Identification of direct targets for the miR-17-92 cluster by proteomic analysis. Proteomics. 2011;11(17):3531\u20139.","journal-title":"Proteomics"},{"issue":"8","key":"761_CR73","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1681\/ASN.2015060634","volume":"27","author":"R Lakhia","year":"2016","unstructured":"Lakhia R, Hajarnis S, Williams D, Aboudehen K, Yheskel M, Xing C, et al. MicroRNA-21 aggravates cyst growth in a model of polycystic kidney disease. J Am Soc Nephrol. 2016;27(8):2319\u201330.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"761_CR74","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1089\/hum.2018.205","volume":"30","author":"J Guo","year":"2019","unstructured":"Guo J, Song W, Boulanger J, Xu EY, Wang F, Zhang Y, et al. Dysregulated expression of microRNA-21 and disease-related genes in human patients and in a mouse model of Alport syndrome. Hum Gene Ther. 2019;30(7):865\u201381.","journal-title":"Hum Gene Ther"},{"issue":"4","key":"761_CR75","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/cells11040594","volume":"11","author":"D Rubel","year":"2022","unstructured":"Rubel D, Boulanger J, Craciun F, Xu EY, Zhang Y, Phillips L, et al. Anti-microRNA-21 therapy on top of ACE ihibition delays renal failure in Alport syndrome mouse models. Cells. 2022;11(4):594.","journal-title":"Cells"},{"issue":"1","key":"761_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053780","volume":"8","author":"H Dweep","year":"2013","unstructured":"Dweep H, Sticht C, Kharkar A, Pandey P, Gretz N. Parallel analysis of mRNA and microRNA microarray profiles to explore functional regulatory patterns in polycystic kidney disease: using PKD\/Mhm rat model. PLoS ONE. 2013;8(1): e53780.","journal-title":"PLoS ONE"},{"issue":"4","key":"761_CR77","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3390\/jcm12041447","volume":"12","author":"F Lanzaro","year":"2023","unstructured":"Lanzaro F, Barlab\u00e0 A, De Nigris A, Di Domenico F, Verde V, Miraglia Del Giudice E, et al. Pediatric diabetic nephropathy: novel insights from microRNAs. J Clin Med. 2023;12(4):1447.","journal-title":"J Clin Med"},{"issue":"1","key":"761_CR78","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1038\/s41467-021-24799-x","volume":"12","author":"H Ding","year":"2021","unstructured":"Ding H, Li LX, Harris PC, Yang J, Li X. Extracellular vesicles and exosomes generated from cystic renal epithelial cells promote cyst growth in autosomal dominant polycystic kidney disease. Nat Commun. 2021;12(1):4548.","journal-title":"Nat Commun"},{"issue":"12","key":"761_CR79","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1681\/ASN.2012030321","volume":"23","author":"V Patel","year":"2012","unstructured":"Patel V, Hajarnis S, Williams D, Hunter R, Huynh D, Igarashi P. MicroRNAs regulate renal tubule maturation through modulation of Pkd1. J Am Soc Nephrol. 2012;23(12):1941\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"761_CR80","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.xkme.2020.06.013","volume":"2","author":"D Li","year":"2020","unstructured":"Li D, Sun L. MicroRNAs and polycystic kidney disease. Kidney Med. 2020;2(6):762\u201370.","journal-title":"Kidney Med."},{"issue":"5","key":"761_CR81","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1752-0509-5-56","volume":"25","author":"P Pandey","year":"2011","unstructured":"Pandey P, Qin S, Ho J, Zhou J, Kreidberg JA. Systems biology approach to identify transcriptome reprogramming and candidate microRNA targets during the progression of polycystic kidney disease. BMC Syst Biol. 2011;25(5):56.","journal-title":"BMC Syst Biol"},{"issue":"9","key":"761_CR82","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1186\/1471-2164-9-624","volume":"23","author":"P Pandey","year":"2008","unstructured":"Pandey P, Brors B, Srivastava PK, Bott A, Boehn SN, Groene HJ, et al. Microarray-based approach identifies microRNAs and their target functional patterns in polycystic kidney disease. BMC Genomics. 2008;23(9):624.","journal-title":"BMC Genomics"},{"issue":"21","key":"761_CR83","first-page":"195","volume":"15","author":"L Sun","year":"2015","unstructured":"Sun L, Zhu J, Wu M, Sun H, Zhou C, Fu L, et al. Inhibition of MiR-199a-5p reduced cell proliferation in autosomal dominant polycystic kidney disease through targeting CDKN1C. Med Sci Monit. 2015;15(21):195\u2013200.","journal-title":"Med Sci Monit"},{"issue":"4","key":"761_CR84","doi-asserted-by":"publisher","first-page":"F577","DOI":"10.1152\/ajprenal.00607.2016","volume":"312","author":"AJ Streets","year":"2017","unstructured":"Streets AJ, Magayr TA, Huang L, Vergoz L, Rossetti S, Simms RJ, et al. Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression. Am J Physiol Renal Physiol. 2017;312(4):F577\u201388.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"761_CR85","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133785","volume":"5","author":"R Lakhia","year":"2020","unstructured":"Lakhia R, Yheskel M, Flaten A, Ramalingam H, Aboudehen K, Ferr\u00e8 S, et al. Interstitial microRNA miR-214 attenuates inflammation and polycystic kidney disease progression. JCI Insight. 2020;5(7): e133785.","journal-title":"JCI Insight."},{"issue":"2","key":"761_CR86","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1096\/fj.201800563RR","volume":"33","author":"DY Kim","year":"2019","unstructured":"Kim DY, Woo YM, Lee S, Oh S, Shin Y, Shin JO, et al. Impact of miR-192 and miR-194 on cyst enlargement through EMT in autosomal dominant polycystic kidney disease. FASEB J. 2019;33(2):2870\u201384.","journal-title":"FASEB J"},{"issue":"1","key":"761_CR87","doi-asserted-by":"publisher","first-page":"14151","DOI":"10.1038\/s41598-017-14083-8","volume":"7","author":"YM Woo","year":"2017","unstructured":"Woo YM, Kim DY, Koo NJ, Kim YM, Lee S, Ko JY, et al. Profiling of miRNAs and target genes related to cystogenesis in ADPKD mouse models. Sci Rep. 2017;7(1):14151.","journal-title":"Sci Rep"},{"issue":"1","key":"761_CR88","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/0886022X.2020.1745236","volume":"42","author":"G Liu","year":"2020","unstructured":"Liu G, Kang X, Guo P, Shang Y, Du R, Wang X, et al. miR-25-3p promotes proliferation and inhibits autophagy of renal cells in polycystic kidney mice by regulating ATG14-Beclin 1. Renal Fail. 2020;42(1):333\u201342.","journal-title":"Renal Fail"},{"issue":"1","key":"761_CR89","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12882-017-0600-z","volume":"18","author":"I Kocyigit","year":"2017","unstructured":"Kocyigit I, Taheri S, Sener EF, Eroglu E, Ozturk F, Unal A, et al. Serum micro-rna profiles in patients with autosomal dominant polycystic kidney disease according to hypertension and renal function. BMC Nephrol. 2017;18(1):179.","journal-title":"BMC Nephrol"},{"issue":"3","key":"761_CR90","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5603\/PJNNS.a2021.0026","volume":"55","author":"A Kulesza","year":"2021","unstructured":"Kulesza A, Kulesza A, Fliszkiewicz M, \u0141abu\u015b A, P\u0105czek L, Niemczyk M. miRNA-16 as a predictive factor for intracranial aneurysms in autosomal dominant polycystic kidney disease. Neurol Neurochir Pol. 2021;55(3):306\u20139.","journal-title":"Neurol Neurochir Pol"},{"issue":"1","key":"761_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086856","volume":"9","author":"IZ Ben-Dov","year":"2014","unstructured":"Ben-Dov IZ, Tan YC, Morozov P, Wilson PD, Rennert H, Blumenfeld JD, et al. Urine microRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline. PLoS ONE. 2014;9(1): e86856.","journal-title":"PLoS ONE"},{"issue":"11","key":"761_CR92","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1681\/ASN.2016111232","volume":"28","author":"V Tesar","year":"2017","unstructured":"Tesar V, Ciechanowski K, Pei Y, Barash I, et al. Bosutinib versus placebo for autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2017;28(11):3404\u201313.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"761_CR93","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1073\/pnas.1011498108","volume":"108","author":"V Takiar","year":"2011","unstructured":"Takiar V, Nishio S, Seo-Mayer P, et al. Activating AMP activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA. 2011;108(6):2462\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"761_CR94","unstructured":"ClinicalTrials.gov. NCT03918447. Available from: https:\/\/www.clinicaltrials.gov. Accessed 10 Dec 2024."},{"issue":"1","key":"761_CR95","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1053\/j.gastro.2010.04.010","volume":"139","author":"SA Gradilone","year":"2010","unstructured":"Gradilone SA, Masyuk TV, Huang BQ, et al. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic chol angiocytes from an animal model of ARPKD. Gastroenterology. 2010;139(1):304-14.e2.","journal-title":"Gastroenterology"},{"issue":"6","key":"761_CR96","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/ki.2011.139","volume":"80","author":"NX Chen","year":"2011","unstructured":"Chen NX, Moe SM, Eggleston-Gulyas T, et al. Calcimimetics inhibit renal pathology in rodent nephronophthisis. Kidney Int. 2011;80(6):612\u20139.","journal-title":"Kidney Int"},{"issue":"7","key":"761_CR97","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1681\/ASN.2008090927","volume":"20","author":"VH Gattone 2nd","year":"2009","unstructured":"Gattone VH 2nd, Chen NX, Sinders RM, et al. Calcimimetic inhibits late-stage cyst growth in ADPKD. J Am Soc Nephrol. 2009;20(7):1527\u201332.","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"761_CR98","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.4161\/cc.22375","volume":"11","author":"NO Bukanov","year":"2012","unstructured":"Bukanov NO, Moreno SE, Natoli TA, et al. CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle. 2012;11(21):4040\u20136.","journal-title":"Cell Cycle"},{"issue":"5","key":"761_CR99","doi-asserted-by":"publisher","first-page":"F944","DOI":"10.1152\/ajprenal.00387.2010","volume":"299","author":"T Yamaguchi","year":"2010","unstructured":"Yamaguchi T, Reif GA, Calvet JP, et al. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol. 2010;299(5):F944\u201351.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"761_CR100","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1267\/ahc.08040","volume":"42","author":"Y Okumura","year":"2009","unstructured":"Okumura Y, Sugiyama N, Tanimura S, et al. ERK regulates renal cell proliferation and renal cyst expansion in inv mutant mice. Acta Histochem Cytochem. 2009;42(2):39\u201345.","journal-title":"Acta Histochem Cytochem"},{"issue":"1","key":"761_CR101","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1038\/s41598-018-22938-x","volume":"8","author":"Y Liu","year":"2018","unstructured":"Liu Y, Pejchinovski M, Wang X, et al. Dual mTOR\/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease. Sci Rep. 2018;8(1):5584.","journal-title":"Sci Rep"},{"issue":"51","key":"761_CR102","doi-asserted-by":"publisher","first-page":"21819","DOI":"10.1073\/pnas.0911987106","volume":"106","author":"Y Cao","year":"2009","unstructured":"Cao Y, Semanchik N, Lee SH, et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD mod els. Proc Natl Acad Sci USA. 2009;106(51):21819\u201324.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"761_CR103","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000369149","volume":"129","author":"C Zoja","year":"2015","unstructured":"Zoja C, Corna D, Locatelli M, et al. Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease. Nephron. 2015;129(1):52\u201361.","journal-title":"Nephron"},{"issue":"8","key":"761_CR104","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nm1783","volume":"14","author":"X Li","year":"2008","unstructured":"Li X, Magenheimer BS, Xia S, et al. A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med. 2008;14(8):863\u20138.","journal-title":"Nat Med"},{"issue":"9","key":"761_CR105","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3727\/096368914X684619","volume":"24","author":"F Franchi","year":"2015","unstructured":"Franchi F, Peterson KM, Xu R, et al. Mesenchymal stromal cells improve renovascular function in polycystic kidney disease. Cell Transplant. 2015;24(9):1687\u201398.","journal-title":"Cell Transplant"},{"issue":"5","key":"761_CR106","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/13543784.2024.2342327","volume":"33","author":"I Capelli","year":"2024","unstructured":"Capelli I, Lerario S, Ciurli F, Berti GM, Aiello V, Provenzano M, et al. Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights. Expert Opin Investig Drugs. 2024;33(5):469\u201384.","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00761-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-024-00761-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00761-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:17:05Z","timestamp":1740467825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-024-00761-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1007\/s40291-024-00761-7","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"type":"print","value":"1177-1062"},{"type":"electronic","value":"1179-2000"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"1 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Caterina Vitulano, Gianmario Forcina, Simone Colosimo, Vittoria Frattolillo, Annalisa Valentina Villani, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, and Anna Di Sessa have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}